FDA Drugs· FDA·· 3 hours agoPickScore94
FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations
In brief
On October 26, 2026, the FDA approved talazoparib combined with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer harboring HRR gene mutations.
Why it matters
Randomized double-blind data from 599 patients give rPFS differences and hazard ratios, plus OS maturity and key safety warnings, enabling benefit-risk comparison.
Source: FDA Drugs · fda.gov